Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years.

ABSTRACT:

Background

Herpes zoster (HZ) and HZ ophthalmicus (HZO) are associated with an increased risk of cardiovascular complications, such as acute myocardial infarction (AMI) and stroke. We evaluated the association between recombinant zoster vaccine (RZV) and risk of HZO, hospitalized AMI, and hospitalized stroke in adults ≥50 years of age (YoA) at Kaiser Permanente Southern California.

Methods

We conducted a matched cohort analysis of adults ≥50 YoA who received 2 doses of RZV 4 weeks-6 months apart during 01 April 2018-31 December 2020 and were matched 1:4 to RZV-unvaccinated individuals on age, sex, race/ethnicity, and index date (date of second dose among vaccinated; unvaccinated match assigned same date). Follow-up started at index date and ended at receipt of zoster vaccine

SUBMITTER: Rayens E 

PROVIDER: S-EPMC12728275 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature